143 results on '"Wheatley-Price, Paul"'
Search Results
2. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
3. Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%
4. Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis
5. What Is Ailing Oncology Clinical Trials? Can We Fix Them?
6. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
7. Three Decades of Malignant Pleural Mesothelioma: An Academic Center Experience
8. Traitement ciblé oral contre le cancer du poumon non à petites cellules.
9. New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.
10. Oral targeted therapy for the treatment of non–small cell lung carcinoma.
11. Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.
12. Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer
13. Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes
14. Involvement of Palliative Care in Malignant Pleural Mesothelioma Patients and Associations with Survival and End-of-Life Outcomes.
15. Radical Treatment of Stage II Non–small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes
16. The Impact of Baseline Edmonton Symptom Assessment Scale Scores on Treatment and Survival in Patients With Advanced Non–small-cell Lung Cancer
17. A prospective intervention to improve happiness and reduce burnout in oncologists
18. The influence of season and distance to a cancer centre on lung cancer treatment rates
19. The utility of H2 receptor antagonists in preventing infusion‐related reactions to paclitaxel chemotherapy.
20. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
21. Patients With Advanced Non–Small Cell Lung Cancer Requiring Inpatient Medical Oncology Consultation: Characteristics, Referral Patterns, and Outcomes
22. Medical Assistance in Dying in Patients With Cancer.
23. What Attributes Matter Most in Physicians? Exploratory Findings from a Single-Centre Survey of Stakeholder Priorities in Cancer Care at a Canadian Academic Cancer Centre.
24. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.
25. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
26. Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer.
27. Management of Very Early Small Cell Lung Cancer: A Canadian Survey Study.
28. Chemotherapy in the oldest old: The feasibility of delivering cytotoxic therapy to patients 80 years old and older
29. Prognostic Factors in the Radical Nonsurgical Treatment of Stage IIIB Non–Small-Cell Lung Cancer
30. Thymic Epithelial Neoplasms: A 12-Year Canadian Regional Cancer Program Experience
31. Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis
32. Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial.
33. Factors Influencing a Specific Pathologic Diagnosis of Non–Small-Cell Lung Carcinoma
34. Incidence and consequences of bone metastases in lung cancer patients
35. Stereotactic Body Radiotherapy (SBRT) in Very Limited-Stage Small Cell Lung Cancer (VLS-SCLC).
36. Risk Model–Guided Antiemetic Prophylaxis vs Physician’s Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial
37. Access to Cancer Drugs in Canada.
38. Prevention and Management of Bone Metastases in Lung Cancer: A Review
39. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer.
40. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study
41. Resident preparedness in discussing prognosis in patients with advanced lung cancer
42. The Mayan Doomsday’s effect on survival outcomes in clinical trials
43. Determinants of the Cancer Drug Funding Process in Canada.
44. Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer.
45. Closing the Gaps to Timely Patient Access: Perspectives on Conditional Funding Models.
46. The Pathway for New Cancer Drug Access in Canada.
47. Complex Germline K757N Mutation in Non-Small-Cell Lung Cancer: A Case Report.
48. The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials
49. The Influence of Sex in Non-Small Cell Lung Cancer
50. Canadian Consensus Recommendations on the Management of MET-Altered NSCLC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.